CytoRecovery
CytoRecovery: Pioneering microfluidic technology for efficient recovery and analysis of biological cells.
Founded
2017CytoRecovery: Pioneering microfluidic technology for efficient recovery and analysis of biological cells.
Founded with the mission to revolutionize cell biology research, CytoRecovery specializes in manufacturing advanced microfluidic technology. Their core vision is to empower life science researchers by providing tools that enable the rapid selection and recovery of rare, homogeneous, and viable cell subpopulations from various biological samples such as tissue and blood. The company's primary products include innovative cell sorting and recovery systems designed to maintain cells in their native, untouched state, thereby ensuring high confidence in downstream applications like culture and analysis.
CytoRecovery has garnered attention from notable figures in the biotechnology and life sciences sectors, attracting investment from key industry players. The company has achieved significant milestones, including the successful commercialization of its microfluidic platforms, which have been widely adopted by research institutions and laboratories. By enhancing the efficiency and accuracy of cell recovery processes, CytoRecovery has made a substantial impact on the field of cell biology, facilitating advancements in research and therapeutic development.
Companies similar to CytoRecovery include CytoMag, NanoCellect Biomedical, CellFE and RareCyte.
CytoRecovery was founded in 2017.
CytoRecovery's headquarters is located in Blacksburg, VA, US.
CytoRecovery's most recent funding round was for $256k (USD) in March 2021.
As of Mar 3, 2021, CytoRecovery has disclosed funding of $256k (USD). Undisclosed round amounts are excluded.
CytoRecovery has 5 employees as of Feb 5, 2024.
RareCyte
rarecyte.com
